Search
Rivanicline
go.drugbank.com/drugs/DB05855ExperimentalIt was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. … It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis.
Tegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalTegafur (INN, BAN, USAN) is a prodrug of [DB00544] (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. … It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327].
Clomifene
go.drugbank.com/drugs/DB00882ApprovedInvestigationalA triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Lexibulin
go.drugbank.com/drugs/DB05147InvestigationalCYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias
Bentiromide
go.drugbank.com/drugs/DB00522ApprovedWithdrawnBentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy. It is typically administered orally. C...
Ifenprodil
go.drugbank.com/drugs/DB08954ApprovedInvestigationalWithdrawn] it has also been shown to have an immunomodulatory effect. … [A220133] Further studies elucidated that ifenprodil binds strongly at the inter-subunit interface of adjacent GluN1 and GluN2B NTDs, where it acts as a non-competitive antagonist.
C31G
go.drugbank.com/drugs/DB05398InvestigationalC31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment
Sunvozertinib
go.drugbank.com/drugs/DB18925Investigational[A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor